NCT01199068View on ClinicalTrials.gov

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

CS-7017

CS-7017 from 0.25 mg to 0.50 mg twice daily

DRUG

Erlotinib

Erlotinib 150 mg once daily

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

ICON Clinical Research
All Listed Sponsors
collaborator

ICON Clinical Research

INDUSTRY

lead

Daiichi Sankyo Co., Ltd.

INDUSTRY